Cushings Syndrome - A Pipeline Analysis Report

Overview of the drug development for Cushing’s syndrome

It has been observed that Cushing’s syndrome results from the long-term exposure to cortisol. Cortisol is the body’s stress hormone. The concentration of cortisol can increase in the body either due to cortisol supplement or because of the overproduction of cortisol. Untreated Cushing’s syndrome can lead to high blood pressure, bone loss, and sometimes type 2 diabetes. Often, the disease is classified in two types including Endogenous Cushing’s syndrome and Exogenous Cushing’s syndrome. Endogenous glucocorticoid overproduction or hypercortisolism, can be dependent on or independent of adrenocorticotropic hormone (ACTH). While Exogenous Cushing’s syndrome is found in individuals taking cortisol-like medications such as prednisone, it is a temporary condition and goes away once intake of cortisol-like medications stopped. According to the NIH, Cushing’s syndrome most often affects adults aged 30-50 years, but can also occur in children. Cushing’s syndrome affects about three times as many women as men. More than 10 million Americans take glucocorticoids each year, but it is not known how many of them develop Cushing’s syndrome. As a result, with the rising incidences of the disease, the need for the drug development for Cushing’s syndrome is expected to increase considerably in the next few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for endogenous Cushing’s syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Cushing’s syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Cortendo
• ElexoPharm
• Millendo Therapeutics
• Novartis

Therapeutic assessment of the drug development for Cushing’s syndrome by route of administration

• Oral

The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for Cushing’s syndrome by therapy

Acccording to this pipeline analysis report, all the molecules that are currently in the drug development for Cushing’s syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for Cushing’s syndrome?
• What are the companies that are currently involved in the development of drug molecules for Cushing’s syndrome?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.